To ensure the quality and safety of medical services in primary healthcare institutions, China’s National Health Commission (NHC) and other relevant authorities issued a notice on 1 April 2026, outlining a three-year nationwide action.

Microplate-based automatic blood grouping analyzer Metis of Aikang MedTech Co., Ltd. (henceforth referred to as Aikang) received approval for marketing in 2015; and its MGT-based automatic blood grouping analyzer Aigel received approval for marketing in 2016.

Eurobio Scientific said on Thursday that its molecular SARS-CoV-2 test for detecting viral variants has received CE marking.

The US Food and Drug Administration this week granted Emergency Use Authorization for the Cleveland Clinic's SelfCheck Cobas SARS-CoV-2 + Flu Assay.

Shanghai Rigen Biotech Co., Ltd. (hereinafter referred to as "Rigen") recently completed a new round of financing of nearly 100 million CNY.

The US Food and Drug Administration on Thursday announced it has granted Emergency Use Authorization to InspectIR Systems' InspectIR COVID-19 Breathalyzer test, making it the first breath-based test for detecting SARS-CoV-2 to receive such designation.

Shanghai Fosun Pharmaceutical on Thursday announced that China's National Medical Products Administration (NMPA) has granted approval for Fosun Diagnostic's Novel Coronavirus (2019-nCoV) Antigen Detection Kit (Colloidal Gold) for COVID-19 screening.

On April 13, the SARS-CoV-2 Rapid Antigen Test (immunochromatography Assay) developed by Sansure Biotech Inc. has obtained CE certification! This means that the test can be sold in EU countries and countries that recognize EU CE certification.

C2i Genomics launches minimal residual disease test across Europe after clearing regulatory hurdles in the EU, UK, and Switzerland.

BioMérieux on Tuesday announced it has entered into an agreement to acquire Specific Diagnostics for an acquisition price equivalent to 3.3 percent of BioMérieux's market capitalization as of April 11, paid with a combination of cash and shares issued to Specific Diagnostics shareholders.

On April 13, National Medical Products Administrations (NMPA) reviewed and approved Zhuhai Livzon Diagnostics Inc. and Shanghai BioGerm Medical Technology Co., Ltd's COVID-19 Antigen Test.

The US Food and Drug Administration last week granted separate Emergency Use Authorizations for a PCR-based SARS-CoV-2 test developed by the University of California, San Diego and an at-home nasal specimen collection kit from the Washington D.C. Department of Health.